| 黄丽艳 鲍路明 哈申高娃 龚翠琴 九姑娘.紫杉醇、长春瑞滨联合顺铂方案治疗晚期乳腺癌的临床疗效[J].现代生物医学进展英文版,2015,15(2):251-253. |
| 紫杉醇、长春瑞滨联合顺铂方案治疗晚期乳腺癌的临床疗效 |
| The Clinical Effect of Paclitaxel or Vinorelbine Combined with Cisplatin inthe Treatment of Advanced Breast Cancer |
| |
| DOI： |
| 中文关键词: 紫杉醇 长春瑞滨 顺铂 晚期乳腺癌 |
| 英文关键词: Paclitaxel Vinorelbine Cisplatin Advanced Breast cancer |
| 基金项目: |
|
| Hits: 953 |
| Download times: 658 |
| 中文摘要: |
| 目的： 探讨紫杉醇（ PTX）、长春瑞滨（ NVB）两药与 顺铂（ DDP）联用方案对晚期乳腺癌的临床疗效及副 反应。 方法： 将 2009 年
2 月至 2014 年 2 月 于我院就诊的 60 例 晚期乳腺癌患者随机分为 TP 方案和 NP 方案两组， 每组 30 例。 TP 方案组： 顺铂 25
mg/m2， d1~d3， 紫杉醇 175 mg/m2， d1； NP 方案组： 顺铂 25 mg/m2， d1 ~d3，长春瑞滨 25 mg/m2， d1 和 d8。 比较两组患者的临床有效率
并记录相关不良反应。 结果： TP 方案有效率 56.7%(1 7/30)，中位缓解期 7.5 个月 。 NP 方案有效率 53.3% (1 4/30)，中位缓解期 7.7 个
月 。 组间 疗效及缓解期差异无统计学意义（ P>0.05）。 TP 与 NP 方案组出现血小板减少、白 细胞减少、贫血、恶心呕吐的发生率分别
为 26.7%、76.7%、 56.7%、 43.3%和 26.7%、 76.7%、 56.7%、43.3%， 两方案血液毒性差异无统计学意义（ P>0.05）。 静脉炎及关节肌肉
反应的发生率分别为 30.0%、 1 3.3%和 1 6.7%53.3%，差异有统计学意义（ P<0.05）。 结论： 紫杉醇、长春瑞滨与 顺铂联用 治疗 晚期乳
腺癌疗效相当 ，不良反应可耐受，都可做为晚期乳腺癌治疗的一线用 药方案。 |
| 英文摘要: |
| Objective:To study the efficacy and toxicities of paclitaxel (PTX) and vinorelbine (NVB) combined with cisplatin
(DDP) in the treatment of advanced breast cancer.Methods:The 60 cases of patients with advanced breast cancer in our hospital from
February 2009 to February 2014 were randomly divided into TP and NP group with 30 cases in each group. The patients in the TP
therapy group received PTX plus DDP ( PTX 175 mg/m2, d1 ; DDP25 mg/m2, d1 ~d3)for treatment; and the patients in the NP therapy
group received the NVB plus DDP (NVB 25 mg/m2, d1 , d8, DDP 25 mg/m2, d1~d3). The clinical effects of two groups were compared
and the related adverse reactions were recorded.Results:In NP group, effective rate was 53.3% (14/30), and in TP group, the effective
rate was 56.7% (1 7/30). The median response duration of NP and TP groups was 7.7 and 7.5 months respectively. The efficacy and
median response duration were not significantly different between the two groups (P>0.05). The incidence rate of leucocyte reducing,
plaque decreasing, vomiting and anemia in TP group and NP group were 26.7%, 76.7%, 56.7%, 43.3% and 26.7%, 76.7%, 56.7%, 43.3%
respectively, there was no statistically significant difference in hematological toxicity between the two regimen groups (P>0.05). The
incidence rates of phlebitis and arthritis were 30.0%, 13.3% and 1 6.7% , 53.3% ,with no difference between the two groups (P<0.05).Conclusion:TP and NP therapies for advanced breast cancer have similar efficacies and fewer adverse reactions, thus can be used as
first-line treatment methods for advanced breast cancer. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
